American National Registered Investment Advisor’s Vertex Pharmaceuticals VRTX Stock Holding History

American National Registered Investment Advisor’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$756K	Sell	2,897 -84	-3%	-$19.9K	0.27%	107
2021 Q4	$655K	Hold	2,981	–	–	0.22%	142
2021 Q3	$541K	Sell	2,981 -7	-0.2%	-$1.37K	0.2%	161
2021 Q2	$602K	Sell	2,988 -25	-0.8%	-$5.23K	0.22%	155
2021 Q1	$647K	Sell	3,013 -2	-0.1%	-$439	0.25%	129
2020 Q4	$713K	Hold	3,015	–	–	0.28%	110
2020 Q3	$820K	Hold	3,015	–	–	0.37%	80
2020 Q2	$875K	Hold	3,015	–	–	0.44%	74
2020 Q1	$717K	Hold	3,015	–	–	0.45%	71
2019 Q4	$660K	Hold	3,015	–	–	0.33%	93
2019 Q3	$511K	Hold	3,015	–	–	0.28%	113
2019 Q2	$553K	Hold	3,015	–	–	0.31%	107
2019 Q1	$555K	Sell	3,015 -10	-0.3%	-$1.85K	0.31%	108
2018 Q4	$501K	Hold	3,025	–	–	0.31%	111
2018 Q3	$583K	Buy	3,025 +255	+9%	+$45.4K	0.31%	109
2018 Q2	$471K	Hold	2,770	–	–	0.23%	156
2018 Q1	$451K	Sell	2,770 -65	-2%	-$10.6K	0.22%	158
2017 Q4	$425K	Buy	+2,835	New	+$420K	0.2%	176

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

American National Registered Investment Advisor's VRTX Position: Q1 2022 in Review

American National Registered Investment Advisor reduced its Vertex Pharmaceuticals (VRTX) stake by 2.8% in Q1 2022, selling an estimated $19.9K and leaving 2,897 shares worth $756K. The position accounts for 0.27% of the portfolio, ranked #107.

American National Registered Investment Advisor first reported a position in VRTX in Q4 2017 and has held it in 18 quarters since. The position peaked at $875K in Q2 2020. 1,073 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

American National Registered Investment Advisor held 2,897 shares of Vertex Pharmaceuticals worth $756K as of Q1 2022.
American National Registered Investment Advisor sold 84 Vertex Pharmaceuticals shares in Q1 2022, an estimated $19.9K.
Vertex Pharmaceuticals made up 0.27% of American National Registered Investment Advisor's portfolio in Q1 2022, its #107 holding.
American National Registered Investment Advisor first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 18 quarters since.
American National Registered Investment Advisor's Vertex Pharmaceuticals position peaked at $875K in Q2 2020.
1,073 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on American National Registered Investment Advisor's 13F filing for Q1 2022, filed 13 May 2022.